Eisai’s policies and programs are supported by full management commitment. We understand that effective management is essential to ensure that policies are implemented correctly, programs help patients in need, and philanthropy achieves its intended impact.
Senior Executive Involvement in Access to Medicines
At Eisai, the Senior Executive responsible for Corporate Affairs has overall responsibility for access strategies and reports on these to the Executive Committee, which is chaired by the company CEO. In addition to ad hoc reporting as required, a report on Eisai’s overall approach to Access to Medicines is delivered to the Executive Committee.
As of July 2017, Mr. Masatomi Akana, Vice President for Corporate Affairs, has overall responsibility for Eisai’s access strategies.
Policy, Advocacy & Sustainability Department
As a specialized department, Eisai's Policy, Advocacy & Sustainability (PAS) Department leads our access to medicines strategies, being responsible for development of new business models, private-public partnerships, and product development partnerships, as well as promotion of Environmental, Social and Governance (ESG) initiatives. In partnership with others inside and outside the company, the PAS Department plans and implements Eisai’s access to medicines related initiatives, and also evaluates the benefits these initiatives bring about to patients and their families. The PAS Department reviews current strategies and discusses new approaches with representatives from relevant organizations within Eisai, and introduces Eisai’s access to medicines initiatives primarily through the corporate website and corporate publications.
Sustainability Advisory Board
Eisai has also established an Sustainability Advisory Board comprised of external experts in international policy to provide high-level guidance for access to medicines and ESG .
In 2011, we formed an Access to Medicines Advisory Board, comprising several experts in international policy and development, to advise us on our strategies and activities to enhance access to medicines so that we can provide patients and their families with solutions sustainably. In 2018, we expanded the scope of "Access to Medicines Advisory Board" and changed it to the "Sustainability Advisory Board" to discuss Eisai’s ESG activities and its goals . In addition to further strengthening access to medicines, we are also working to enhance corporate value by discussing Eisai’s response to climate change and the way the governance system should be with members involved in ESG activities, while taking advice and suggestions from the members of Sustainability Advisory Board.
The current members of Eisai’s Sustainability Advisory Board are:
Mr. Mitsuo SAKABA (Chairman)
Former Ambassador to Vietnam/Belgium. Mr. Mitsuo Sakaba graduated from Yokohama City University and started his career at the Ministry of Foreign Affairs of Japan in 1973. As a trainee of the Ministry, he studied at the Montpellier University in France (1974-76). Following that, he served as Director of Technical Cooperation in charge of JICA in the Economic Cooperation Bureau and as the Counsellor of Permanent Delegation of Japan to the OECD in charge of development cooperation issues. He also served as the Consul-General in Chicago, the Director-General of the Latin American and Caribbean Affairs Bureau, and as Ambassador to Vietnam (2008-10) and the Kingdom of Belgium (2012-14). In September 2014, after leaving the Ministry of Foreign Affairs, he became a Professor of International Politics at Yokohama City University (2015-17). Since January 2017, he is serving as a Member of the Public Security Examination Commission under the Ministry of Justice.
Mr. Ujal Singh BHATIA
Former Indian Ambassador and Permanent Representative to the World Trade Organization (WTO). Mr. Bhatia joined the Indian Administrative Service in 1974 and spent the first two decades of his service career in development administration in the state of Odisha, in Eastern India. Between 1995-2000, he worked in the Central Government in Delhi, as Joint Secretary in the Commerce and Industry Ministry. During this period, he dealt with a range of trade policy issues - domestic, bilateral, regional and multilateral. From 2000-2004, he returned to Odisha and held several senior positions there, including Principal Secretary. From 2004-2010, he served as India's Ambassador and Permanent Representative to the WTO. He is presently a Member of the Appellate Body of the WTO.
Message from Mr. Mitsuo SAKABA (Chairman)
The global landscape is now dramatically changing around the international health environment. Ebola fever in Africa crossed the frontiers and frightened the whole world in 2014-15, exposing serious shortcomings in crisis management of the global health regime. In Asia, we are not immune either to new challenges of infectious diseases as seen in recent cases of SARS, Avian Influenza (Bird Flu) and MERS, while confronting traditional, but still serious diseases of HIV/AIDS, malaria and tuberculosis. The health issue is high on the agenda for deliberating the new global Sustainable Development Goals and human security in United Nations. Against this backdrop, the Japanese Government adopted in 2013 a specific Strategy on Global Health Diplomacy in order to strengthen its contribution in the field of Universal Health Coverage (UHC). The public-private partnership is much encouraged in this regard.
Eisai has been playing an exemplary role in combatting neglected tropical diseases (NTDs) in developing countries. It is well known that Eisai is providing medicines to help WHO fight against Lymphatic Filariasis Endemic, one of the larger scale NTDs. In January 2012, Eisai signed the historic London Declaration which is the largest global public-private partnership aiming at eliminating ten NTDs by 2020 as the only signatory among Japanese pharmaceutical companies. Particular attention should also be paid to the fact that in 2013, Eisai contributed to the launch of the GHIT Fund (Global Health Innovative Technology Fund), the first ever public-private partnership in Japan to eliminate infectious diseases in developing countries. All these contributions by Eisai in the field of “access to medicines (ATM)” are well reflected in the high ranking (no.11) of the company in the ATM index 2014, published by the highly respected ATM Foundation, Netherlands. It is my great pleasure to be a member of Eisai’s ATM team as I spent a large part of my diplomatic career in the field of development cooperation. I am convinced that Eisai, with its World Health Initiative, will make a further contribution to relieve the international community from heavy yokes of infectious diseases.
Message from Mr. Ujal Singh BHATIA
The compulsions of a high cost research driven business model often lead firms to focus primarily on bottom lines. However, firms operating in the human healthcare area have to be aware of a larger responsibility - to ensure that the products of their research are able to reach those who need them most but who may not be able to access them.
It is a recognition of this larger responsibility which drives Eisai's ATM initiative. Eisai’s commitment to ATM is reflected in its continuing search for new business models, public-private partnerships and product development partnerships. The 2010 agreement with the WHO to establish a public-private partnership to combat lymphatic filariasis is an illustration of this commitment. The agreement commits Eisai to supply free of charge, diethylcarbamazine (DEC) to the WHO to enable it to combat this neglected tropical disease in the most endemic regions of the world.
Eisai's participation in the London Declaration, a unique public-private partnership which aims to eliminate 10 NTDs by 2020, is another affirmation of its commitment to the ATM objective. Eisai’s active participation in the Global Health Innovative Technology Fund launched by the government of Japan will enable it to contribute to the discovery and development of global health technologies. Eisai’s premier position among Japanese companies in the Global ATM Index demonstrates that the ATM objective is embedded in the core of Eisai’s business philosophy.
While the objective of ATM is a constant, the policies and strategies required to operationalise it differ from country to country. A market like India for instance, where public healthcare systems are not well developed and where the majority of patients are poor, requires a bespoke approach which takes into account such complexities. I am happy to see the effort being put in to design a pricing and availability strategy for Halavan for the Indian market.
Eisai’s unique commitment to ATM marks it out as a global enterprise with a conscience. I am sure that in the years to come, this commitment can only deepen.